Cytokine Storm Syndrome and Laboratory Testing
Educational Resources for you
While most people with COVID-19 exhibit mild symptoms, approximately one in five develop severe pneumonia.1 Of severe COVID-19 patients, approximately 5% develop a systemic dysregulated cytokine response.1,2 This extreme immune response, called cytokine storm syndrome (CSS), is associated with severe COVID-19 disease and can cause widescale cellular and organ tissue damage.
The use of inflammation, tissue and organ damage biomarkers can help clinicians understand the severity of the disease and implement timely interventions for COVID-19 patients at risk for CSS.
High serum levels of pro- and anti-inflammatory cytokines were found in patients with severe COVID-19.3,4 IL-6 levels were higher in COVID-19 patients who did not survive.5
Tissue and organ damage in patients with CSS can be monitored with a variety of laboratory tests.6
Siemens Healthineers has a robust menu of inflammatory markers (including a key marker, IL-6†) and other lab tests to assess tissue and organ damage.
Staying Ahead of Cytokine Storm Syndrome
Testing for Key Inflammation Markers
AACC webinar: Cytokine Storm Syndrome and COVID-19
Dr. Randy Cron discusses criteria for identifying cytokine storm syndrome (CSS) in patients, complications, and available potential treatments, which include glucocorticoids but also targeted therapies that dampen pro-inflammatory cytokines such as interleukin-1 (IL-1) and IL-6.
Randy Cron, MD, PhD
University of Alabama at Birmingham
Article in Medical Lab Observer (MLO): COVID-19 and Cytokine Storm Syndrome
The authors cover the cause and symptoms of COVID-19 and how severe cases can relate to cytokine storm syndrome (CSS). Also discussed is IL-6† as a CSS biomarker and its potential predictive value for COVID-19 severity.
Educational presentation: COVID-19 and Cytokine Storm Syndrome
This video reviews a variety of COVID-19 and cytokine storm syndrome topics, including immune response to the SARS-CoV-2 virus from normal to extreme (CSS), the role of laboratory testing in detecting tissue damage caused by CSS, and how interleukin-6 (IL-6)† potentially relates to COVID-19 severity.
H. Roma Levy, MS, Medical Writer
† Products are not FDA cleared/approved for sale in the U.S.
Siddiqi HK, et al. J Heart Lung Transplant. 2020. https://doi.org/10.1016/j.healun.2020.03.012.
Zhou Y, et al. National Science Review. 2020. DOI: 10.1093/nsr/nwaa041.
Qin C, et al. Clin Infect Dis. 2020. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa248/5803306.
Del Valle, Kim-Schulze, Huang, et al. https://doi.org/10.1101/2020.05.28.20115758.
Zhou F, et al. The Lancet. 2020. https://doi.org/10.1016/S0140-6736(20)30566-3.
https://www.ifcc.org/ifcc-news/2020-03-26-ifcc-information-guide-on-covid-19/. (Accessed July 23, 2020).